Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study is conducted in China only. The purpose is to demonstrate the efficacy and safety
of once weekly dosing of TransCon hGH, a long-acting growth hormone product, compare to
once-daily dosing of human growth hormone (hGH) after 52 weeks of treatment in prepubertal
children with growth hormone deficiency (GHD).